Figure 3.

Characterization of susceptibility profiles of E. coli isolates in the ESBL/AmpC collection, in a cross‐sectional study performed on healthy adult horses, in France, in 2015 (n = 50 isolates). AMC, amoxicillin‐Clavulanic acid; AMK, Amikacin; AMP, ampicillin; ATM, Aztreonam; CAZ, Cefoperazon; CFP, Ceftazidime; CHL, chloramphenicol; CIP, ciprofloxacin; CN, Cefalexin; CRO, ceftriaxone; CXM, Cefuroxim; ENR, Enrofloxacin; FEP, Cefepime; FFC, Florfenicol; FOX, Cefoxitin; GEN, gentamicin; IPM, Imipenem; KAN, kanamycin; NAL, Nalidixic acid; PIP, Piperacillin; SPT, Spectinomycin; SSS, Sulfisoxazole; STR, streptomycin; TCC, Ticarcillin‐Clavulanic acid; TET, tetracycline; TIC, Ticarcillin; TMP, trimethoprim; TZP, Piperacillin‐Tazobactam; UB, Flumequine; XNL, Ceftiofur